Zhejiang Hisun Pharmaceutical Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Shanghai Xuanchuang Biological Technology Co., Ltd.

Shanghai Suntrong Biotechnology Co., Ltd.

Jinyao Chen

Guobin Ren

Feng Chen

Hua Bai

Changliang Dai

Minghui Qi

Wenming Zhu

Minghuang Hong

Ying Liu

Zhen Zhang

Quanhai Liu

Li Cai

Xuejun Wu

Minyu Liu

Xiaoling Huang

Lin Xiao

Yifang Deng

Yan Qin

Renhai Chen

Haiyan Sun

Zhiru Xu

Chungang Li

Liling Jin

Xiangduan Tan

Tian Zhang

Yinglu Yu

Dongxu Yi

Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.

Pyrroloquinoline quinone glycine betaine salt

The invention discloses a form A of mesylate for nicotinamide derivatives and preparation method and application thereof, wherein the XRPD pattern of the form A of mesylate for nicotinamide derivatives has a diffraction peak at 2&#x3b8;=5.34, 10.341, 14.438, 15.841, 17.32, 18.301, 18.68, 19.005, 19.577, 20.26, 21.161, 21.859, 22.379, 23.04, 23.5, 24.177, 24.959, 25.881, 26.641, 27.18, 28.3, 28.999, 29.501, 31.96, 32.258, 33.999, 36.798, 37.38 and 41.297 with the error range of the 2&#x3b8; values being &#xb1;0.2. The form A of mesylate for nicotinamide derivatives provided by the present invention has excellent high-temperature stability, high-humidity stability and illumination stability, and it can be applied to drugs for treating advanced non-small cell lung cancers, gastric cancers, liver cancer or breast cancer. It has preferable bioavailability, and meanwhile the provided qualitative and quantitative information has great significance on further study of the efficacy of such solid drugs.

Form A of mesylate for nicotinamide derivatives and preparation method and application thereof

Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

Ginsenoside C-K polymorphic compounds and method for preparing same

Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.

Two crystal forms of ginsenoside C-K and method for preparing same

An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.

Amorphous asiatic tromethamine salt and preparation method thereof

Growing community of inventors

Shanghai, China

Jinyao Chen